Novo Nordisk ends deal with Hims & Hers over sales of Wegovy copycats; HIMS drops 20%
1. Novo Nordisk ends collaboration with Hims & Hers over Wegovy concerns. 2. Hims' shares dropped 20% following Novo's announcement. 3. Accusations of deceptive marketing and safety risks for patients cited. 4. Regulatory issues surround compounded versions of Wegovy drugs. 5. Quality concerns arise from Chinese suppliers of Wegovy knock-offs.